Contributors |
|
xi | |
Preface |
|
xv | |
|
1 Introduction to Hematopoietic Stem Cell Transplantation and CellularTherapy |
|
|
1 | (12) |
|
|
|
Allogeneic and Autologous Transplants |
|
|
1 | (1) |
|
Classification of Allogeneic Transplants |
|
|
2 | (4) |
|
Complications of Allogeneic Transplants |
|
|
6 | (4) |
|
|
10 | (1) |
|
|
10 | (3) |
|
2 Autologous and Allogeneic Transplantation for Lymphoma |
|
|
13 | (38) |
|
|
|
I Autologous Stem Cell Transplantation (Austin Kim) |
|
|
13 | (1) |
|
|
13 | (2) |
|
|
15 | (2) |
|
|
17 | (3) |
|
|
20 | (3) |
|
II Allogeneic Stem Cell Transplantation (Eric D. Jacobsen) |
|
|
23 | (1) |
|
|
23 | (8) |
|
|
31 | (3) |
|
Peripheral T-Cell Lymphoma |
|
|
34 | (2) |
|
AlloSCT in Less Common PTCL Subtypes |
|
|
36 | (2) |
|
T-Cell Prolymphocyte Leukemia (T-PLL) |
|
|
38 | (1) |
|
Adult T-Cell Leukemia Lymphoma (ATLL) |
|
|
39 | (1) |
|
Cutaneous T-Cell Lymphoma (CTCL) |
|
|
40 | (2) |
|
|
42 | (1) |
|
|
42 | (7) |
|
|
49 | (2) |
|
3 Autologous Transplantation for Multiple Myeloma |
|
|
51 | (10) |
|
|
|
|
51 | (1) |
|
ASCT in Management of Multiple Myeloma |
|
|
52 | (2) |
|
Mobilization and Conditioning |
|
|
54 | (2) |
|
Consolidation and Maintenance Therapy |
|
|
56 | (1) |
|
|
57 | (1) |
|
|
58 | (1) |
|
|
58 | (3) |
|
4 Allogeneic Hematopoietic Stem Cell Transplantation for Acute and Chronic Leukemias |
|
|
61 | (8) |
|
|
|
61 | (1) |
|
|
61 | (3) |
|
|
64 | (4) |
|
|
68 | (1) |
|
5 Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome |
|
|
69 | (12) |
|
|
|
|
69 | (1) |
|
|
69 | (1) |
|
|
70 | (1) |
|
|
71 | (6) |
|
|
77 | (4) |
|
6 Conditioning Regimen, Graft Sources, and Alternative Donor Transplantation |
|
|
81 | (12) |
|
|
|
|
81 | (1) |
|
Donor Classification and Selection |
|
|
81 | (5) |
|
|
86 | (1) |
|
|
87 | (3) |
|
|
90 | (1) |
|
Clinical Vignette and Self-Assessment |
|
|
91 | (1) |
|
|
91 | (1) |
|
|
92 | (1) |
|
|
92 | (1) |
|
7 Acute Graft-Versus-Host Disease |
|
|
93 | (614) |
|
|
|
|
93 | (1) |
|
|
93 | (2) |
|
|
95 | (2) |
|
|
97 | (1) |
|
|
98 | (3) |
|
Potential Practice Changing Clinical Trials |
|
|
101 | (1) |
|
Clinical Vignettes and Self-Assessment |
|
|
102 | (1) |
|
|
102 | (1) |
|
|
103 | (2) |
|
|
105 | (2) |
|
8 Chronic Graft-Versus-Host Disease |
|
|
107 | (1) |
|
|
|
|
107 | (1) |
|
|
108 | (1) |
|
|
108 | (1) |
|
|
108 | (20) |
|
Clinical Vignettes and Self-Assessment |
|
|
128 | (1) |
|
|
128 | (1) |
|
|
129 | (1) |
|
|
129 | (4) |
|
9 Bacterial and Fungal Infections in Hematopoietic Stem Cell Transplantation Recipients |
|
|
133 | (1) |
|
|
|
|
133 | (5) |
|
|
138 | (2) |
|
|
140 | (5) |
|
|
145 | (3) |
|
|
148 | (1) |
|
10 Viral Infections After Hematopoietic Stem Cell Transplantation |
|
|
149 | (1) |
|
|
|
|
149 | (1) |
|
|
150 | (1) |
|
|
150 | (5) |
|
|
150 | (1) |
|
|
150 | (1) |
|
|
150 | (13) |
|
11 Pulmonary Complications After Hematopoietic Stem Cell Transplantation |
|
|
163 | (1) |
|
|
|
|
163 | (1) |
|
Infectious Pulmonary Complications |
|
|
163 | (5) |
|
Noninfectious Pulmonary Complications |
|
|
168 | (5) |
|
Late Noninfectious Complications |
|
|
173 | (3) |
|
Clinical Vignettes and Self-Assessment |
|
|
176 | (3) |
|
|
176 | (2) |
|
|
178 | (1) |
|
|
179 | (2) |
|
12 Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome |
|
|
181 | (1) |
|
|
|
|
181 | (3) |
|
|
184 | (4) |
|
Treatment and Supportive Care |
|
|
188 | (2) |
|
|
190 | (3) |
|
13 Thrombotic Microangiopathy and Kidney Injury After Hematopoietic Stem Cell Transplantation |
|
|
193 | (1) |
|
|
|
|
|
|
|
193 | (1) |
|
|
193 | (1) |
|
Pathogenesis and Risk Factors |
|
|
194 | (2) |
|
|
196 | (1) |
|
|
197 | (1) |
|
|
197 | (2) |
|
|
199 | (2) |
|
14 Hematologic and Transfusion Issues After Hematopoietic Stem Cell Transplantation |
|
|
201 | (1) |
|
|
|
|
201 | (1) |
|
|
201 | (3) |
|
|
204 | (1) |
|
|
205 | (2) |
|
|
207 | (2) |
|
|
209 | (1) |
|
Clinical Vignettes and Self-Assessment |
|
|
209 | (1) |
|
|
209 | (2) |
|
|
211 | (1) |
|
|
211 | (2) |
|
15 Posttransplant Lymphoproliferative Disorders |
|
|
213 | (1) |
|
|
|
|
213 | (1) |
|
|
213 | (1) |
|
|
214 | (1) |
|
|
214 | (2) |
|
|
216 | (1) |
|
|
216 | (1) |
|
|
217 | (2) |
|
|
219 | (1) |
|
|
219 | (2) |
|
|
221 | (1) |
|
|
|
Mahmoud Deeb Saeed Al Jurf |
|
|
|
221 | (1) |
|
|
221 | (1) |
|
|
222 | (1) |
|
|
222 | (2) |
|
Transplant-Related Factors |
|
|
224 | (2) |
|
|
226 | (1) |
|
|
226 | (2) |
|
|
228 | (3) |
|
17 Treatment of Disease Relapse After Allogeneic Transplantation |
|
|
231 | (1) |
|
|
|
|
231 | (1) |
|
Predicting Risk of Relapse Using Pretransplant Data |
|
|
231 | (2) |
|
Predicting Risk of Relapse With Posttransplant Monitoring |
|
|
233 | (1) |
|
Treating Relapsed Disease: Timing and Approach to Chemotherapy |
|
|
233 | (2) |
|
Treating Relapsed Disease: Enhancing Graft-Versus-Leukemia |
|
|
235 | (3) |
|
|
238 | (1) |
|
|
238 | (5) |
|
18 Chimeric Antigen Receptor T Therapy: Rational and Clinical Applications |
|
|
243 | (1) |
|
|
|
|
243 | (2) |
|
Current Applications and Indications |
|
|
245 | (1) |
|
|
245 | (3) |
|
B-Cell Acute Lymphoblastic Leukemia |
|
|
248 | (1) |
|
Chronic Lymphocytic Leukemia (CLL) |
|
|
249 | (2) |
|
Special Issues: Toxicities |
|
|
251 | (3) |
|
|
254 | (4) |
|
|
258 | (1) |
|
|
259 | (1) |
|
|
260 | (3) |
|
19 Management of Cytokine Release Syndrome |
|
|
263 | (1) |
|
|
|
|
|
263 | (1) |
|
|
263 | (1) |
|
|
264 | (1) |
|
|
265 | (1) |
|
|
265 | (2) |
|
|
267 | (4) |
|
|
271 | (2) |
|
20 Cellular Therapy Neurotoxicity: Diagnosis and Management |
|
|
273 | (1) |
|
|
|
|
|
273 | (1) |
|
|
273 | (12) |
|
|
285 | (3) |
|
|
288 | (1) |
|
|
289 | (2) |
|
Clinical Vignettes and Self-Assessment |
|
|
291 | (3) |
|
|
291 | (2) |
|
|
293 | (1) |
|
|
294 | (3) |
|
21 Quality of Life and Long-Term Survivor Issues: A Review of Recommendations of Long-Term Management |
|
|
297 | (1) |
|
|
|
|
297 | (1) |
|
Late Effects of HCT: Prevention and Follow-Up |
|
|
297 | (7) |
|
|
304 | (2) |
|
Future Research and Directions |
|
|
306 | (1) |
|
Clinical Vignettes and Self-Assessment |
|
|
307 | (1) |
|
|
307 | (1) |
|
|
308 | (1) |
|
|
308 | (1) |
|
|
308 | (1) |
|
22 Biostatisties and Clinical Trials |
|
|
309 | (1) |
|
|
|
309 | (1) |
|
|
309 | (11) |
References |
|
320 | (3) |
Index |
|
323 | |